Early & Late-Stage Venture Capital

With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.

We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.

We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.

33 product approvals
45 M&A / exits
40+ technical experts
64 IPOs

"Abingworth was the first institutional investor to reach out directly to VenatoRx, even before we were looking to fund-raise. They have excellent knowledge of the infectious disease domain space and had clearly done their homework. We enjoy a strong collaborative relationship that adds significant value to the company."

Christopher Burns, CEO of VenatoRx

"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."

Jonas Hansson, CEO of Wilson Therapeutics

"Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor, galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site of our new corporate headquarters in an intensely competitive real estate market."

Grant Pickering, President and CEO of SutroVax

"Working with Abingworth to build CRISPR Therapeutics is a pleasure. They are incredibly supportive in shaping the company, which aims to lead the highly dynamic and competitive environment of gene editing."

Rodger Novak, Chairman of CRISPR Therapeutics

"The business acumen and scientific insight provided by multiple members of the Abingworth team is invaluable to a young company like IFM. We are fortunate to be working with them as we grow and develop the company."

Gary Glick, CEO of IFM Therapeutics